Cell biology is the largest single technology segment in the life science tools market, and “cell biology” is exactly the kind of label that flattens two very different sales motions into one generic pitch.
Single-cell sequencing resolves heterogeneity inside a sample: the rare resistant tumor cells, the transitional immune states, the subpopulations a bulk assay averages away. 3D culture and organoid systems solve a different problem entirely: making a drug screen or disease model behave more like real tissue than a flat plastic dish.
If your product genuinely supports both, congratulations, you also have two distinct buyers, two distinct objections, and two distinct reasons a customer switches. Selling them with one blended message is the single most common mistake we see in this category.
Why “advanced cell biology research” doesn’t convert
A core facility director running single-cell sequencing as a service for a dozen labs evaluates dissociation kits on cell viability and recovery from a specific, often difficult, sample type. A pharma discovery scientist running organoid-based oncology screens evaluates a scaffold material on whether it maintains tissue architecture through repeated drug exposure over weeks.
Neither one cares that your product supports “advanced cell biology.” They care whether it solves the exact failure they’ve already had three times this quarter.
PSG Life Sciences already works across the cell biology market, cell-based discovery and screening services, flow cytometry and high-content analysis, primary and immortalized cell lines, and the 3D culture and microphysiological systems this category runs on. We build the segmented positioning that separates your single-cell story from your organoid story, so each one actually lands.
Where PSG Life Sciences fits
Still defining who buys which workflow and why? Our Start solution builds the ideal customer profile and positioning for each motion, separately distinguishing the core-facility buyer from the discovery-scientist buyer from day one, instead of discovering the difference six months into a flat pipeline.
Already selling, but growth has plateaued past your early adopters? Our Grow solution rebuilds your CRM segmentation and demand generation around workflow type, cell or tissue application, buyer type, and connects trial kit usage to repeat purchase, since both single-cell and organoid consumables carry real recurring revenue if you track it.
Need the CRM itself to actually reflect this segmentation? HubSpot Life Sciences Pro configures pipelines, lead scoring, and reporting so single-cell and organoid leads never get lumped into one undifferentiated “cell biology” bucket again.
What we actually build for single-cell and organoid companies
- Two distinct positioning tracks: one for single-cell resolution use cases, one for 3D/organoid tissue-modeling use cases, with separate content, separate application notes, and separate sales talk tracks
- Core facility account strategy, since many academic single-cell programs are accessed through a shared facility, not purchased by the individual PI
- Pharma and biotech discovery segmentation, treating organoid-based screening buyers as a distinct, often higher-value, sales motion
- CRM tracking for trial-to-repeat-purchase conversion, by cell or tissue type, so reorder patterns actually show up instead of getting buried in aggregate numbers
- Distributor and channel structure for either workflow where direct sales reach is limited
A direct question worth asking yourself
If you stripped your current website copy down to one sentence per workflow, would a single-cell buyer and an organoid buyer each recognize themselves in it, or would they both read the same paragraph and move on?
Ready to stop selling two markets with one message?
PSG Life Sciences is a HubSpot Gold partner and fractional commercialization firm working exclusively with biotech, life science, and diagnostic product companies, including the cell biology, flow cytometry, and 3D culture platforms this market runs on. We build the segmented positioning and CRM systems described above as implemented client work, not theory.